Clinical Trial Update: Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports on a completed Phase 1/2 study of liposomal daunorubicin combined with SU5416 for hematologic cancers that failed initial the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Anemia with Excess Blasts
• Anemia with Excess Blasts in Transformation
• Myelodysplastic Syndrome
• Myelomonocytic Leukemia

Drugs mentioned

• Liposomal daunorubicin (daunorubicin liposome)
• SU5416 (semaxanib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: COMPLETED